Pulmonx Corp (LUNG) said after close Wednesday that it lost $0.36 per share in quarter four 2023.
On the revenue line, the company reported $19.3 million, beating estimates by $1 million.
In the same quarter a year ago, the company lost $0.38 per share on revenue of $15.4 million.
The stock is down 16.55% to $12.10 after the report.
Despite revenues increasing, earnings decreased, signaling a decline in profit margins.
The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.
InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.
Prior to the report, InvestorsObserver gave the stock an overall score of 66. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
News Home
Pulmonx Corp Down 16.55% To $12.10 After Earnings Beat
Mentioned in this article
